Table 3.
ZIKV vaccine candidates in clinical development.
| Vaccine strategy | Candidate name | Sponsor | Non-clinical development | Phase 1 | Phase 2 | References |
|---|---|---|---|---|---|---|
| DNA | GLS-5700 | GeneOne Life Science, Inc. Inovio Pharmaceuticals vio | Immunogenicity in mice and NHP |
NCT02809443 NCT02887482 |
(134, 135) | |
| VRC5283 | NIAID/VRC | Immunogenicity in mice and NHP; efficacy in NHP | NCT02996461 | NCT03110770 | (136, 137) | |
| VRC5288 | NCT02840487 | |||||
| mRNA | mRNA-1325 | Moderna Therapeutics | Immunogenicity and efficacy in mice | NCT03014089 | (138) | |
| mRNA-1893 | Efficacy in mice | NCT04064905 | (139) | |||
| Whole inactivated | ZPIV | NIAID/WRAIR/BIDMC | Immunogenicity and efficacy in mice and NHP |
NCT02963909 NCT02952833 NCT02937233 NCT03008122 |
(97, 98, 140) | |
| BBV121 | Bharat Biotech International | Immunogenicity and efficacy in mice | CTRI/2017/05/008539 | (141) | ||
| PIZV (TAK-426) | Takeda Pharmaceuticals | Immunogenicity and efficacy in mice | NCT03343626 | (142) | ||
| VLA1601 | Valneva Austria GmbH /Emergent Biosolutions | NCT03425149 | ||||
| Live attenuated | rZIKV/D4Δ30-713 | NIAID | NCT03611946 | |||
| Viral vectored | MV-ZIKA | Themis Bioscience GmbH | Immunogenicity in mice; efficacy in pregnant mice | NCT02996890 | (143) | |
| MV-ZIKA RSP | NCT04033068 |